Traders should await the official year-end financial results in the upcoming 10-K filing for audited figures. This preliminary cash update provides limited insight but may offer some confidence in the company's near-term liquidity position.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $128.60entry
- T+1 · 9mo ago +15.35%α +15.90% · $148.34
- T+5 · 9mo ago +5.36%α +6.46% · $135.49
- T+20 · 8mo ago −6.38%α −1.15% · $120.39
- T+60 · 6mo ago −10.19%α −17.14% · $115.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics, Inc. announced preliminary cash, cash equivalents, and marketable securities of approximately $55.9 million as of December 31, 2025. This figure is unaudited, preliminary, and subject to change upon completion of the company's financial closing procedures. No other financial results or operational metrics were disclosed.
Key Facts
- Company reported preliminary cash, cash equivalents, and marketable securities of $55.9 million as of December 31, 2025
- The financial data is preliminary, unaudited, and has not been reviewed by the company's independent auditors
- The final reported amount may differ materially from this estimate
- No revenue, earnings, guidance, or other operational results were disclosed in this filing
Financial Impact
Approximately $55.9 million in cash and marketable securities (preliminary)
Risk Factors
- The $55.9 million figure is preliminary and may change significantly upon audit
- No information on revenue, expenses, or profitability was provided
- Investors lack context on cash burn rate or runway implications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-019143 |
| Document: 0001104659-26-019143-index-headers.html | 0001104659-26-019143 |
| Document: 0001104659-26-019143-index.html | 0001104659-26-019143 |
| Document: 0001104659-26-019143.txt | 0001104659-26-019143 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers